Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients

Abstract

-Purpose: The adrenoceptor family, as one of the main contributors in regulating the noradrenergic system, has been studied in involvement of depression and its treatment. A functional polymorphism of G1165C on beta adrenoceptor (βAR) enhances post receptor signalling and is assumed to be involved in pharmacotherapy of depression. The aim of the present study was to discern the influence of G1165C polymorphism in the β1AR gene on individual differences in response to sertraline. Methods: One hundred newly diagnosed patients completed 6 weeks of sertraline treatment. Response to treatment was defined as a 50% decrease in Hamilton Rating Scale for depression (HRSD). Results: The patients who carried CC genotype responded five times more to sertraline comparing with other variants (P=0.005; OR=5.7; 95%CI=1.4-23.9). Moreover, carriers of C allele responded three times more to sertraline than patients with the G allele (P=0.001; OR= 3.3; 95%CI= 1.72-6.50). Conclusion:In conclusion, our results support the hypothesis that genetic variation of β1AR might influence clinical response to sertraline.

Association study of the beta-adrenergic receptor genetic variant Gly389Arg and fluoxetine response in major depression

“…According to our knowledge, role of G1165C polymorphism in efficacy of response to fluoxetine in a set of newly diagnosed Iranian MDD patients has not been conducted to date. Although a previous study on MDD patients treated with sertraline showed a strong association between G1165C polymorphism and response to sertraline [29], our study on another antidepressant of the same class (SS-RIs), fluoxetine shows no association with better response to treatment. Considering that this study also investigated one hundred MDD patients, it seems that lack of association between the mentioned polymorphism and response to fluoxetine is not due to sample size.…”

“…A study by Crowley et al showed lack of association between the functional polymorphism of G1165C and response to citalopram in depressed patients [28]. Another study carried out by Firouzabadi et al examining the effect of the same polymorphism in response to sertraline suggested that the patients who carried CC genotype responded five times more to sertraline in comparison with other variants and carriers of C allele responded three times more to sertraline than patients with the G allele [29]. According to our knowledge, role of G1165C polymorphism in efficacy of response to fluoxetine in a set of newly diagnosed Iranian MDD patients has not been conducted to date.…”

DRD3 Ser9Gly Polymorphism and Its Influence on Risperidone Response in Autistic Children

“…As a means of targeted treatment and personalized medicine, pharmacogenetics has currently drawn a lot of attention in many neurologic and psychiatric diseases (36)(37)(38)(39)(40). Although many studies have focused on the contribution of genetic factors in autism (41,42), their role as therapeutic elements stays illusive.…”

Characteristics of arterial hypertension clinical course in patients with obesity and anxiety-depressive disorders

“…в литературе имеются данные о том, что пациенты с генотипом СС функционального полиморфизма G1165C позитивно реагировали на лечение сертралином в 5 раз чаще по сравнению с другими вариантами генотипа (ОШ 5,7, p=0,005). кроме того, носители аллеля C в 3 раза чаще позитивно реагировали на сертралин, чем пациенты с аллелем G (p=0,001; ОШ 3,3) [63]. Носители аллеля Del генотипа DelDel полиморфизма (I/D) rs4291 в гене ангиотензинпревращающего фермента значительно лучше реагировали на терапию сертралином, чем флуоксетином (p=0,0006, ОШ 3,0 и p=0,006, ОШ 3,7).…”